Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, when his Department plans to make a decision on whether to refer for consideration by NICE PRRNT treatment for pancreatic cancers.

The National Institute for Health and Care Excellence (NICE) has recently consulted stakeholders on the suitability of Lutetium-177 Dotatate - a type of peptide receptor radionuclide therapy (PRRT) - for treating unresectable, somatostatin receptor-positive gastroentero-pancreatic neuroendocrine tumours without disease progression for referral to its technology appraisal work programme. A decision on its referral to NICE will be taken shortly.